Hydroxocobalamin
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Hydroxocobalamin
- Generic name
- HYDROXOCOBALAMIN
- Manufacturer
- Xseer Pharmaceuticals
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 3be23e83-4a7f-3854-e063-6294a90acb7a
- SPL ID
- 51e3535b-dc11-abe8-e063-6394a90a0c61
- Version
- 2
- Effective date
- 2026-05-15
- Source export date
- 2026-09-28
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/663999d0fe1757c1e2cd13a4799d76d875f663e0bc57701092264ebe7febfc18/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:27:39
| Harmonized routes |
|---|
| INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Hydroxocobalamin | openfda.brand_name | |
| generic name | HYDROXOCOBALAMIN | openfda.generic_name | |
| manufacturer name | Xseer Pharmaceuticals | openfda.manufacturer_name | |
| ndc | package | 85551-125-30 | openfda.package_ndc |
| ndc | product | 85551-125 | openfda.product_ndc |
| ndc11 | package | 85551012530 | derived:openfda.package_ndc |
| rxcui | 317106 | openfda.rxcui | |
| spl id | 51e3535b-dc11-abe8-e063-6394a90a0c61 | id | |
| spl set id | 3be23e83-4a7f-3854-e063-6294a90acb7a | set_id | |
| unii | Q40X8H422O | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings and Precautions Hypersensitivity reactions, including anaphylactic shock, rash, pruritus, urticaria, and edema, have been reported following parenteral administration of vitamin B12 products, including hydroxocobalamin. Patients with known sensitivity to hydroxocobalamin, cobalt, benzyl alcohol, or any component of the formulation may be at increased risk for serious allergic reactions. This product contains benzyl alcohol as a preservative. Benzyl alcohol has been associated with serious and fatal adverse reactions, including “gasping syndrome,” in premature infants and neonates. Administer under appropriate medical supervision. Monitor patients for signs and symptoms of hypersensitivity during administration. Do not use if the solution is cloudy, discolored, or contains particulate matter. Use aseptic technique during handling and administration. Protect from light. Not for intravenous administration.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
Adverse Reactions The following adverse reactions have been reported with hydroxocobalamin injection and other parenteral vitamin B12 products: Hypersensitivity reactions including anaphylactic shock, urticaria, rash, pruritus, flushing, and edema Injection site pain, erythema, and injection site reactions Headache and dizziness Nausea and diarrhea Fever and chills Rare cases of hypokalemia during intensive treatment of severe megaloblastic anemia Serious hypersensitivity reactions, including anaphylaxis, may occur in sensitive patients. To report suspected adverse reactions, contact Xseer Pharmaceuticals at (888) 658-8005 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.